Tag Archives: accelerated; elotuzumab; infusion rate; monoclonal antibody; multiple myeloma

A Phase 2 Study of Accelerated Elotuzumab Infusion, over Less than 1 Hour, in Combination with Lenalidomide and Dexamethasone, in Patients with Multiple Myeloma

March 5, 2017


Abstract Elotuzumab, an immunostimulatory SLAMF7-targeting monoclonal antibody, induces myeloma cell death with minimal effects on normal tissue. In a previous phase 3 study in patients with relapsed/refractory multiple myeloma (RRMM), elotuzumab (10 mg/kg, ∼3-hour infusion), combined with lenalidomide and dexamethasone, demonstrated durable efficacy and acceptable safety; 10% (33/321) of patients had infusion reactions (IRs; Grade […]

Continue reading...
Scroll Up